[go: up one dir, main page]

TW200801200A - Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist - Google Patents

Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist

Info

Publication number
TW200801200A
TW200801200A TW095129405A TW95129405A TW200801200A TW 200801200 A TW200801200 A TW 200801200A TW 095129405 A TW095129405 A TW 095129405A TW 95129405 A TW95129405 A TW 95129405A TW 200801200 A TW200801200 A TW 200801200A
Authority
TW
Taiwan
Prior art keywords
gpr109a
individual
probability
receptor
amino acid
Prior art date
Application number
TW095129405A
Other languages
English (en)
Inventor
Chen W Liaw
Martha Kanemitsu-Parks
Jeremy G Richman
Dominique Maciejewski-Lenoir
Daniel T Connolly
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of TW200801200A publication Critical patent/TW200801200A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095129405A 2005-08-10 2006-08-10 Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist TW200801200A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70737205P 2005-08-10 2005-08-10
PCT/US2006/031032 WO2007021744A1 (en) 2005-08-10 2006-08-09 Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist

Publications (1)

Publication Number Publication Date
TW200801200A true TW200801200A (en) 2008-01-01

Family

ID=37496834

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095129405A TW200801200A (en) 2005-08-10 2006-08-10 Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist

Country Status (4)

Country Link
US (1) US20090117559A1 (zh)
EP (1) EP1924709A1 (zh)
TW (1) TW200801200A (zh)
WO (1) WO2007021744A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331521T3 (es) 2003-11-21 2010-01-07 Arena Pharmaceuticals, Inc. Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo.
AU2006247695B2 (en) 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007087204A2 (en) 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
US20170042821A1 (en) * 2007-07-01 2017-02-16 Vitalis Llc Combination tablet with chewable outer layer
WO2011057110A1 (en) * 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
RU2612575C2 (ru) * 2011-07-15 2017-03-09 Конинклейке Филипс Н.В. Обработка изображений для спектральной компьютерной томографии
GB2497766A (en) * 2011-12-20 2013-06-26 Gene Onyx Ltd Snp analysis to determine efficacy of skin care product
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds

Also Published As

Publication number Publication date
EP1924709A1 (en) 2008-05-28
US20090117559A1 (en) 2009-05-07
WO2007021744A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
CA2735578C (en) Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
Johnston et al. Genome‐wide association mapping identifies the genetic basis of discrete and quantitative variation in sexual weaponry in a wild sheep population
WO2008013910A3 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
WO2008029130A3 (en) Method of detecting and predicting ovulation and the period of fertility
TW200801200A (en) Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
NZ598009A (en) Genetic markers associated with risk of diabetes mellitus
NZ591711A (en) A method for predicting athletic performance potential
WO2010103292A3 (en) A genotyping tool for improving the prognostic and clinical management of ms patients
WO2019204340A3 (en) Biomarker for predicting equine gait and methods of use thereof
WO2004002296A3 (en) Therapeutic methods for reducing fat deposition and treating associated conditions
WO2003072828A3 (en) Fcgammariib polymorphisms detection in system lupus erythematosus
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
EP1531180A4 (en) METHOD FOR DIAGNOSIS OF MYOCARDINE RISK
IL174195A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
WO2009011297A1 (ja) Jak2遺伝子の変異検出用プローブおよびその用途
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
NZ593392A (en) Biomarker for detecting bladder cancer
WO2007025989A3 (en) Nucleic acid variants in the toll like receptor genes associated with altered innate immunity
IL182383A (en) Double hybrid system based on gene silencing by transcriptional interference
GB0713364D0 (en) Abnormal blood conditions
DE602004021366D1 (zh)
ATE449189T1 (de) Diagnose- und prognoseverfahren der nichtalkoholischen steatohepatitis (nash)
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis
EP1767653A4 (en) PROBE FOR THE DIAGNOSIS OF MARFANS SYNDROME AND METHOD FOR SCREENING WITH THE PROBE